Nausea and Vomiting after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis

Wang, Shi Ying; Zhu, Wen; Vargulick, Sonya; Lin, Sam Bill; Meng, Zhi Qiang

doi:10.7314/apjcp.2013.14.10.5995

Cited by 18 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was also pointed out in a previous study by Siriwardana et al 2 Another study by Wang et al 18 also showed that female gender correlates with a higher incidence of postprocedural nausea, particularly in premenopausal women. 18 In that study, they found no statistically significant difference in the incidences of nausea and vomiting between male over 50 years and female patients who have entered menopause, a finding that raised the suspicion that these associations could be due to hormonal causes, namely the estradiol level. However, in our study, all women included both in the cases and control groups were postmenopausal, so this explanation is not applicable.…”

Section: Discussionsupporting

confidence: 69%

Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment

et al. 2018

View full text Add to dashboard Cite

RESUMOIntrodução: A quimioembolização hepática é uma técnica amplamente usada para o tratamento do carcinoma hepatocelular. A principal complicação deste procedimento é a síndrome pós-quimioembolização. O principal objetivo deste estudo foi determinar fatores de risco para síndrome pós-quimioembolização. Material e Métodos: Análise retrospetiva unicêntrica de 563 procedimentos de quimioembolização hepática efetuados entre 1/1/2014-31/12/2015. A quimioembolização hepática foi efetuada com ½ -2 ampolas de microesferas 100 -300 μm carregadas com doxorrubicina. Os pacientes que desenvolveram síndrome pós-quimioembolização foram identificados pelo prolongamento do internamento por dor, febre, náuseas e/ou vómitos. Um grupo controlo com os pacientes que não desenvolveram síndrome pós-quimioembolização foi criado de forma randomizada (três controlos para um caso). Foi realizada análise descritiva e regressão logística multivariada. Resultados: A prevalência global de síndrome pós-quimioembolização foi 6,2%. Quimioembolização hepática com dose de doxorrubicina superior a 75 mg (mais de uma ampola), o tamanho do nódulo maior e o género feminino demonstraram relação estatisticamente significativa com o desenvolvimento de síndrome pós-quimioembolização (p = 0,030, p = 0,046 e p = 0,037, respetivamente , 2015. Hepatic transarterial chemoembolization was performed with ½ -2 vials of 100 -300 μm microspheres loaded with doxorubicin. Patients who experienced postembolization syndrome were identified based on prolongation of hospitalization due to pain, fever, nausea and/or vomiting. A control group with the patients who did not have postembolization syndrome was randomly created (three controls for one case). Descriptive analysis and multivariate logistic regression were performed. Results: The overall prevalence of postembolization syndrome was 6.2%. Hepatic transarterial chemoembolization with doxorubicin dosage above 75 mg (more than one vial), the size of the largest nodule and female gender had statistically significant relation with development of postembolization syndrome (p = 0.030, p = 0.046 and p = 0.037, respectively). Discussion: Doxorrubicin dosage above 75 mg is associated with a higher risk of postembolization syndrome. This result can be helpful for decision-making in clinical practice, whenever it is possible to avoid a higher dose without compromising the efficacy of the treatment. The size of the largest nodule and female gender also constitute risk factors for postembolization syndrome. The other variables studied were not related to the development of postembolization syndrome. Conclusion:The dose of doxorrubicin, the size of the largest nodule treated and female gender are potential risk factors for the development of postembolization syndrome after hepatic transarterial chemoembolization for hepatocellular carcinoma.

show abstract

Section: Discussionsupporting

confidence: 69%

Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…TACE, due to its Minimal invasive and good outcome, had become one of the important palliative treatments for the patients with advanced HCC (Si et al, 2013;Wang SY, et al, 2013;Cui L, et al, 2012;Kong WD, et al, 2012). With the development of the high efficiency and low toxicity antitumor drugs, More kinds of chemotherapy regimens include LBP (a third generation platinum) were used with TACE and got the better effect.…”

Section: Discussionmentioning

confidence: 99%

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Zhao

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…These techniques have also improved tolerance by making treatment as selective as possible, which has been shown to be one of the most important factors for reducing pain and the post‐embolization syndrome . Nevertheless, there are very few studies evaluating the risk factors of poor tolerance in patients treated with up‐to‐date selective TACE . A recent study by Hucke et al .…”

mentioning

confidence: 99%

Risks factors for severe pain after selective liver transarterial chemoembolization

Benzakoun

Ronot

Lagadec

et al. 2016

Liver International

View full text Add to dashboard Cite

show abstract

Nausea and Vomiting after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis

Cited by 18 publications

References 20 publications

Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment

Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Risks factors for severe pain after selective liver transarterial chemoembolization

Contact Info

Product

Resources

About